Findings

What do systematic reviews say?

47 questions · 47 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 4.3%GRADE not reported 1 · 2.1%Very low 21 · 44.7%Low 14 · 29.8%Moderate 9 · 19.1%High 0 · 0%

Azathioprine vs infliximab

Adverse events · Patients with active Crohn's disease

Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.01 [0.93, 1.08]
1 study · 324 participants
Moderate

Azathioprine vs placebo

Any adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
RR 2.51 [0.82, 7.74]
4 studies · 232 participants
Very low

Azathioprine vs infliximab

Serious adverse events · Patients with active Crohn's disease

Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.12 [0.77, 1.62]
1 study · 324 participants
Moderate

Azathioprine vs budesonide

Serious adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 5.13 [0.25, 103.43]
1 study · 77 participants
Very low

Azathioprine vs infliximab

Withdrawals due to adverse events · Patients with active Crohn's disease

Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.47 [0.96, 2.23]
1 study · 324 participants
Moderate

Azathioprine vs budesonide

Withdrawals due to adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 5.13 [0.25, 103.43]
1 study · 77 participants
Very low

Azathioprine vs methotrexate

Severe adverse events · adults with renal vasculitis for maintenance therapy

Azathioprine may leads to lower severe adverse events compared with methotrexate (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.58
1 study · 126 participants
Low

Azathioprine vs cyclophosphamide

Serious adverse events · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.18 [0.45, 3.07]
1 study · 144 participants
Moderate

Azathioprine + infliximab vs infliximab

Adverse events · Patients with active Crohn's disease

Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.01 [0.94, 1.09]
1 study · 342 participants
Moderate

Azathioprine vs no intervention

Serious adverse events (proportion) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine + infliximab vs infliximab

Adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.6 [0.33, 7.86]
1 study · 45 participants
Very low

Azathioprine vs no intervention

Serious adverse events (number of events) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.89 [0.74, 1.07]
4 studies · 346 participants
Low

Azathioprine or 6‐mercaptopurine vs anti TNF‐ɑ

Adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with anti TNF‐α (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.13 [0.83, 1.53]
2 studies · 117 participants
Low

Azathioprine or 6‐mercaptopurine vs placebo

Adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.36 [0.57, 3.27]
2 studies · 168 participants
Low

Azathioprine or 6‐mercaptopurine vs methotrexate

Adverse events · Patients with active Crohn's disease

Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.42 [0.21, 0.82]
2 studies · 85 participants
Low

Azathioprine or 6‐mercaptopurine vs placebo

Adverse events · maintenance of remission in Crohn's disease

Azathioprine or 6‐mercaptopurine may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.29 [1.02, 1.64]
6 studies · 359 participants
Low

Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine

Adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 8.77 [0.54, 142.51]
1 study · 45 participants
Very low

Azathioprine vs methotrexate

Adverse event causing death or study drug discontinuation · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.58 [0.25, 1.38]
1 study · 126 participants
Low

Azathioprine + infliximab vs infliximab

Serious adverse events · Patients with active Crohn's disease

Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.63 [0.41, 0.98]
1 study · 342 participants
Moderate